Maha H. Hussain, MD, FACP, FASCO

Maha H. Hussain, MD, FACP, FASCO

Northwestern University

Chicago, Illinois

Maha H. Hussain, MD, FACP, FASCO, is the deputy director of the Lurie Cancer Center. In this role, Hussain plays a critical role in establishing the overall strategic direction, policy and priorities of the Lurie Cancer Center. She is integrally involved in all aspects of operations and functions as the senior leader in the director's absence. Maha H. Hussain, MD, is also responsible for the development and oversight of clinical research in the Lurie Cancer Center, including the coordination of all cancer-related clinical research services throughout the Lurie Cancer Center and Northwestern Medicine. She chairs the Governance Committee of the Clinical Research Office and serves on the Clinical Cancer Center Executive Council and the Lurie Cancer Center Executive Committee. She also provides leadership for clinical faculty recruitment and oversees the Translational Research in Solid Tumors and Hematological Malignancies Programs in the Lurie Cancer Center. Hussain is the Genevieve E. Teuton Professor of Medicine and a professor of Medicine in the Division of Hematology/Oncology at the Feinberg School of Medicine. Her research efforts are focused on the development of novel therapeutics integrating scientific advances into clinical trials for prostate and bladder cancer. Hussain's extensive national scientific leadership roles include serving as co-chair of the Prostate Cancer Subcommittee/Genitourinary Cancer Committee of SWOG, where she guided research in areas of advanced prostate cancer that led to changing standards of care. She has served as a member and chair of the Integration Panel of the U.S. Army Medical Research and Materiel Command Prostate Cancer Research Program and as a member and chair of the U.S. Food and Drug Administration Oncology Drug Advisory Committee. Prior to joining the Lurie Cancer Center in September 2016, she was associate director for Clinical Research at the University of Michigan Cancer Center.

Articles by Maha H. Hussain, MD, FACP, FASCO

PROfound Trial Shows Increased rPFS in mCRPC Patients with BRCA1, BRCA2, and ATM Mutations

Maha H. Hussain, MD, FACP, FASCO, and Celestia S. Higano, MD, discuss the PROfound Trial, which demonstrated increased radiographic progression-free survival (rPFS) with the use of olaparib for mCRPC patients displaying the genetic mutations BRCA1, BRCA2, and ATM. Dr. Hussain outlines previous research of genetic mutations in mCRPC that led to this study, the study design and rationale of using two cohorts with specific mutations (BRCA1, BRCA2, and ATM) and non-specific mutations (other genetic alterations), and results that demonstrate promise for gene-targeted therapies in the future.

Read More

Join the GRU Community

- Why Join? -